🚨🧬 Mirai Bio Raises $50M to Revolutionize Genetic Medicine Development 🚀 Mirai Bio, a Cambridge-based bioplatform innovation company, has secured $50M in initial funding! 💰 The founding investment was made by Flagship Pioneering, fueling the next stage of genetic medicine advancement across a wide range of therapeutic areas. 🌍 🔬 What makes Mirai Bio unique? Led by CEO Geoffrey von Maltzahn, Mirai Bio has built a machine intelligence-driven platform that addresses the key limitations in genetic medicine—delivery, design, and manufacturing. 💡 Their open platform leverages high throughput automation and in vivo multiplexing to rapidly generate data and optimize delivery to any tissue or cell type. This allows for faster, more efficient breakthroughs in genetic therapies. 🧠💥 💡 Why it matters: Mirai Bio’s technology accelerates genetic medicine development, creating a path for the next generation of treatments across a variety of diseases and therapeutic modalities. 🔍 This investment marks a significant leap toward transforming the future of healthcare. 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #GeneticMedicine #BiotechInnovation #MachineIntelligence #FundingNews #HealthcareRevolution #FutureTechly
